Tom Werner
Merck (NYSE:MRK) and Eisai (OTCPK:ESALF) Tuesday said that their Phase 3 LITESPARK-011 trial met a key goal, showing improved progression-free survival for patients with advanced kidney cancer treated with a combination of Merck’s Welireg and Eisai’s Lenvima.
LITESPARK-011 marks the